Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eloralintide - Eli Lilly and Company

Next Previous
Drug Profile

Eloralintide - Eli Lilly and Company

Alternative Names: Amylin agonist LA - Eli Lilly and Company; Amylin agonist long acting - Eli Lilly and Company; LY-3841136

Latest Information Update: 27 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antihyperglycaemics; Antirheumatics; Obesity therapies; Sleep disorder therapies
  • Mechanism of Action Amylin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Obesity; Osteoarthritis; Sleep apnoea syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 27 Feb 2026 Eli Lilly and Company plans a phase I trial for Kidney disorders in USA (SC) in February 2026 (NCT07426380)
  • 11 Feb 2026 Eli Lilly and Company plans the phase III ENLIGHTEN-6 trial in Obesity (Treatment-experienced) in USA, Australia, Belgium, Brazil, China, Czech Republic, India, Israel, Japan, Mexico, Puerto Rico, Romania, Spain, Taiwan (SC) (NCT07392190) (EUCT2025-523659-73-00)
  • 11 Feb 2026 Eli Lilly and Company plans a phase I trial for Liver failure in the US and Hungary (SC) in 28 February 2026 (NCT07401862)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top